People: Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

10:52pm IST
Change (% chg)

$0.40 (+0.64%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Fetzer, Oliver 

Dr. Oliver S. Fetzer Ph.D. is an Independent Director of the Company. Dr. Fetzer has served on our Board of Directors since February 2017. He has served as the Chief Executive Officer of Synthetic Genomics, Inc., a private synthetic biology company commercializing genomic technologies, since November 2014. Prior to Synthetic Genomics, Dr. Fetzer was President and Chief Executive Officer of Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, from April 2009 to October 2014. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and of Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG, a publicly traded provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 149,969
Long-Term Incentive Plans, USD --
All Other, USD 190,603
Fiscal Year Total, USD 340,572

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tina Nova


Amit Munshi


Kevin Lind


Steven Spector


Vincent Aurentz


Preston Klassen

As Of  31 Dec 2018